Clinical Trials Directory

Trials / Sponsors / Tiziana Life Sciences LTD

Tiziana Life Sciences LTD

Industry · 13 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Multiple System Atrophy
Phase 22025-05-19
RecruitingNasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-Active Secondary Progressive Multiple Sclerosis
Phase 22025-03-04
RecruitingA Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Secondary Progressive Multiple Sclerosis
Phase 22023-11-15
UnknownMilciclib in Combination With Gemcitabine in Advanced NSCLC
NSCLC
Phase 22023-03-15
WithdrawnA Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Crohn's Disease
Phase 12022-05-01
WithdrawnIn-patient COVID-19 Study of Intranasal Foralumab
Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
Phase 22022-04-30
WithdrawnPhase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
Phase 12021-10-01
CompletedSafety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
Safety, Tolerability
Phase 12018-11-12
WithdrawnAssessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
Phase 22017-12-01
CompletedStudy of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Phase 22017-07-12
TerminatedStudy Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemot
Malignant Thymoma
Phase 22011-02-02
TerminatedPhase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Thymic Carcinoma
Phase 22010-02-22
AvailableIntermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patient
Non-Active Secondary Progressive Multiple Sclerosis
——